Nascent Biotech (NBIO) Stock Price, News & Analysis

Company Overview

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Key Stats

• Today's Range: $0.03 to $0.06
• 50-Day Range: $0.03 to $0.08
• 52-Week Range: $0.03 to $0.19
• Volume: 607,823 shs
• Average Volume: 174,932 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NBIO Stock Analysis - Frequently Asked Questions

How have NBIO shares performed this year?

Nascent Biotech's stock was trading at $0.0506 at the beginning of the year. Since then, NBIO shares have decreased by 37.5% and is now trading at $0.0316.
View the best growth stocks for 2025 here.

How do I buy shares of Nascent Biotech?

Shares of NBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Nascent Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nascent Biotech investors own include Fulcrum Therapeutics (FULC), Evelo Biosciences (EVLO), VIVUS (VVUS), Applied Therapeutics (APLT), Ocugen (OCGN), Processa Pharmaceuticals (PCSA) and Rigel Pharmaceuticals (RIGL).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NBIO
• CUSIP: N/A
• CIK: 1622057
• Web: www.nascentbiotech.com
• Phone: (612) 961-5656
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A